Log in Free sign up

Allogene Therapeutics (ALLO) News and press releases

News

From Benzinga Pro

What 5 Analyst Ratings Have To Say About Allogene Therapeutics

Analyst Ratings

Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Oppenheimer Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $35

News, Price Target, Analyst Ratings

Oppenheimer analyst Mark Breidenbach maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $40 to $35.

RBC Capital Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $32

News, Price Target, Analyst Ratings

RBC Capital analyst Luca Issi maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $35 to $32.

Raymond James Downgrades Allogene Therapeutics to Market Perform

News, Downgrades, Analyst Ratings

Raymond James analyst Dane Leone downgrades Allogene Therapeutics (NASDAQ:ALLO) from Outperform to Market Perform.

Allogene Therapeutics: Q2 Earnings Insights

Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Allogene Therapeutics Q2 EPS $(0.52) Beats $(0.61) Estimate

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.61) by 14.75 percent. This is a 1.89 percent increase over losses of $(0.53) per share

Earnings Scheduled For August 9, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch

Analyst Color, Penny Stocks, Small Cap, Top Stories, Analyst Ratings, Trading Ideas

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a list of potential short squeeze stocks based on S3's proprietary Squeeze Score rating

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

12 Health Care Stocks Moving In Friday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Goldman Sachs Upgrades Allogene Therapeutics to Buy, Raises Price Target to $32

News, Upgrades, Price Target, Analyst Ratings

Goldman Sachs analyst Salveen Richter upgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Buy and raises the price target from $9 to $32.

89 Biggest Movers From Friday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

What 4 Analyst Ratings Have To Say About Allogene Therapeutics

Analyst Ratings

Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:

Baird Initiates Coverage On Allogene Therapeutics with Neutral Rating, Announces Price Target of $11

News, Price Target, Initiation, Analyst Ratings

Baird analyst Jack Allen initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Neutral rating and announces Price Target of $11.

Goldman Sachs Maintains Neutral on Allogene Therapeutics, Lowers Price Target to $9

News, Price Target, Analyst Ratings

Goldman Sachs maintains Allogene Therapeutics (NASDAQ:ALLO) with a Neutral and lowers the price target from $12 to $9.

Press releases

From Benzinga Pro

Allogene Therapeutics Reports Second Quarter 2022 Financial Results

Earnings, News, Health Care, Press Releases

U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry's First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2 Protocol and Chemistry

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

News, Press Releases

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

News, Press Releases

SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)

Thinking about buying stock in Allogene Therapeutics, Neximmune, Vertical Aerospace, Sonim Technologies, or DigitalBridge?

Opinion, Press Releases

NEW YORK, July 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALLO, NEXI, EVTL, SONM, and DBRG.

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

Health Care, Press Releases

RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American Society of Hematology (ASH) 2021